AstraZeneca recently announced plans for the expansion of its biologics manufacturing center in Frederick, Md., which will add approximately 40,000 additional square feet of manufacturing, laboratory and administrative space and 300 new jobs to the site. The more than $200 million project will increase production capacity at the facility to support AstraZeneca’s maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline.
AstraZeneca recognizes and thanks the many partners that made this expansion a reality, including the state of Maryland, Frederick County and the City of Frederick.
“We’re growing our economy by investing in education, infrastructure, and innovation — biotech and AstraZeneca are critical pieces of fostering innovation,” said Maryland Governor Martin O’Malley. “AstraZeneca’s expansion in Frederick reinforces Maryland’s position as an epicenter for the bioscience industry, and we’re pleased by the company’s continued commitment to driving innovation and bringing high-quality jobs to the state.”
AstraZeneca’s Frederick biologics manufacturing center is an FDA licensed, large-scale cell culture production facility, with hundreds of thousands of square feet of administrative, production, warehouse, laboratory and utility space. The expansion project is anticipated to begin in December and expected to be complete in mid-2017.
“Biologics are an important part of AstraZeneca’s overall capabilities, in addition to our strengths in small molecules and protein engineering,” said Andrew D. Skibo, regional vice president of biologics supply for AstraZeneca. “Our global biologics research and development arm, MedImmune, has a robust pipeline of more than 120 biologics, including more than 30 in clinical development. The expansion of our Frederick facility will support the progression of drug candidates across our core therapeutic areas, ultimately aiding us in our efforts to make a meaningful difference in the lives of patients through scientific leadership and innovative new treatments.”
AstraZeneca’s Frederick manufacturing center is the largest biologics manufacturing facility within the company’s global network and portfolio of assets, and a worldwide industry leader in cell culture manufacturing. The site currently produces a pediatric medication, as well as other investigational biologic products.
AstraZeneca’s Maryland operations are integral to our global business, and to the development, manufacturing and marketing of innovative biopharmaceuticals that benefit patients worldwide. In addition to the Frederick facility, our Gaithersburg, Md. Campus, which is home to MedImmune, is one of three global research and development centers (along with Cambridge, UK and Mölndal, Sweden) designated to improving pipeline productivity and establishing the company as a global leader in biopharmaceutical innovation.